Results 101 to 110 of about 1,683,745 (416)

P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

HemaSphere, 2022
S. Venugopal, H. kantarjian, A. Maiti, N. Short, G. Montalban-Bravo, Y. Alvarado, K. S. Chien, R. Kanagal-Shamanna, N. Pemmaraju, N. Daver, T. Kadia, G. Borthakur, E. Jabbour, G. Garcia-Manero   +13 more
doaj   +1 more source

‘Acute myeloid leukemia: a comprehensive review and 2016 update'

Blood Cancer Journal, 2016
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an incidence of over 20 000 cases per year in the United States alone.
I. De Kouchkovsky, M. Abdul-Hay
semanticscholar   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

HemaSphere, 2022
K. Chien, K. Kim, Z. Li, R. Kanagal Shamanna, F. Ong, G. Montalban Bravo, T. Kadia, E. Jabbour, N. Pemmaraju, D. Hammond, N. Short, F. Ravandi, Y. Alvarado, S. Pierce, X. Q. Dong, H. Kantarjian, G. Garcia-Manero   +16 more
doaj   +1 more source

Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics

Haematologica, 2013
The significance of flow cytometry indicating myelodysplasia without proof of myelodysplasia by cytomorphology remains to be clarified. We evaluated follow-up analyses in 142 patients analyzed in parallel by flow cytometry, cytomorphology and ...
Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Tamara Alpermann, Torsten Haferlach   +4 more
doaj   +1 more source

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2019
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States.
M. Tallman, E. Wang, J. Altman, F. Appelbaum, V. Bhatt, D. Bixby, S. Coutre, M. de Lima, A. Fathi, M. Fiorella, J. Foran, Aric Hall, Meagan A. Jacoby, J. Lancet, T. Leblanc, G. Mannis, G. Marcucci, Mike G Martin, A. Mims, M. O'donnell, R. Olin, D. Peker, A. Perl, D. Pollyea, K. Pratz, T. Prebet, F. Ravandi, P. Shami, R. Stone, S. Strickland, M. Wieduwilt, K. Gregory, Lydia Hammond, Ndiya Ogba   +33 more
semanticscholar   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

Molecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi   +11 more
wiley   +1 more source

S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY

HemaSphere, 2022
M. Yilmaz, M. Muftuoglu, H. Kantarjian, C. DiNardo, T. Kadia, G. Borthakur, N. Pemmaraju, N. Short, Y. Alvarado, A. Maiti, L. Masarova, G. Montalban Bravo, S. Loghavi, K. Patel, S. Kornblau, E. Jabbour, G. Garcia-Manero, M. Andreeff, N. Daver   +18 more
doaj   +1 more source

Recurring mutations found by sequencing an acute myeloid leukemia genome.

New England Journal of Medicine, 2009
BACKGROUND The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of
E. Mardis, L. Ding, D. Dooling, D. Larson, M. McLellan, Ken Chen, D. Koboldt, R. Fulton, K. Delehaunty, S. McGrath, L. Fulton, Devin P. Locke, V. Magrini, R. Abbott, T. Vickery, Jerry S. Reed, J. Robinson, T. Wylie, Scott M. Smith, Lynn K. Carmichael, James M. Eldred, C. Harris, Jason R. Walker, Joshua B. Peck, Feiyu Du, Adam Dukes, Gabriel E. Sanderson, Anthony M. Brummett, Eric Clark, Joshua F. McMichael, R. Meyer, Jonathan K Schindler, C. Pohl, J. Wallis, Xiaoqi Shi, Ling Lin, Heather K. Schmidt, Yuzhu Tang, C. Haipek, Madeline E. Wiechert, Jolynda V Ivy, Joelle Kalicki, Glendoria Elliott, R. Ries, J. Payton, P. Westervelt, M. Tomasson, M. Watson, J. Baty, S. Heath, W. Shannon, R. Nagarajan, D. Link, M. Walter, T. Graubert, J. Dipersio, R. Wilson, T. Ley   +57 more
semanticscholar   +1 more source

The Topology of Mutated Driver Pathways [PDF]

arXiv, 2019
Much progress has been made, and continues to be made, towards identifying candidate mutated driver pathways in cancer. However, no systematic approach to understanding how candidate pathways relate to each other for a given cancer (such as Acute myeloid leukemia), and how one type of cancer may be similar or different from another with regard to their
arxiv